CERS vs EMBC
CERS: Cerus is a developer of blood safety technologies, specifically pathogen reduction systems designed to protect the blood supply from transfusion-transmitted infections. EMBC: A dedicated diabetes care company specializing in insulin delivery systems and pen needles for millions of users worldwide.
Side-by-side fundamentals
| Metric | CERS | EMBC | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $2.15 | $3.64 | |
| Market cap as of 2026-08-03 | $433M | $216M | |
| P/E as of 2026-08-03 | n/a | 1.92 | |
| PEG as of 2026-08-03 | n/a | -0.19 | |
| Net margin as of 2026-08-03 | -3.9% | +10.7% | EMBC higher |
| Gross margin as of 2026-08-03 | +58.4% | +61.9% | EMBC higher |
| Operating margin as of 2026-08-03 | -1.3% | +25.8% | EMBC higher |
| ROE as of 2026-08-03 | -15.4% | +6.1% | EMBC higher |
| ROA as of 2026-08-03 | -4.4% | +10.3% | EMBC higher |
| Debt / equity as of 2026-08-03 | 1.26 | 0.00 | EMBC lower |
| Revenue growth (YoY) as of 2026-08-03 | +18.4% | -3.4% | CERS higher |
| Revenue CAGR (3y) SEC XBRL | +7.5% | -1.5% | CERS higher |
| Dividend yield as of 2026-08-03 | n/a | +1.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 4 | |
| Beta as of 2026-08-03 | 1.66 | 0.89 | |
| 1-year return as of 2026-07-31 close | +68.0% | -64.2% | CERS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.